CG
HZNP

Caprock Group’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Caprock Group’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,784
Closed -$203K – 685
2022
Q4 		$203K Buy
+1,784
New +$148K 0.02% 501
2022
Q2 		– Sell
-1,959
Closed – – 652
2022
Q1 		$0 Buy
1,959
+73
+4% +$7.11K ﹤0.01% 671
2021
Q4 		$203K Sell
1,886
-258
-12% -$28.1K 0.02% 542
2021
Q3 		$235K Buy
2,144
+8
+0.4% +$831 0.02% 458
2021
Q2 		$200K Buy
+2,136
New +$197K 0.02% 501
2021
Q1 		– Sell
-4,555
Closed -$333K – 552
2020
Q4 		$333K Hold
4,555
– – 0.04% 303
2020
Q3 		$354K Sell
4,555
-1,700
-27% -$117K 0.05% 261
2020
Q2 		$348K Sell
6,255
-4,539
-42% -$194K 0.05% 258
2020
Q1 		$320K Sell
10,794
-367
-3% -$12.4K 0.06% 223
2019
Q4 		$404K Sell
11,161
-150
-1% -$4.6K 0.07% 198
2019
Q3 		$308K Sell
11,311
-995
-8% -$25.7K 0.06% 233
2019
Q2 		$296K Hold
12,306
– – 0.06% 240
2019
Q1 		$325K Sell
12,306
-304
-2% -$7.2K 0.06% 251
2018
Q4 		$246K Buy
+12,610
New +$247K 0.06% 279

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Caprock Group's HZNP Position: Q1 2023 in Review

Caprock Group sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2023, closing a stake of 1,784 shares — an estimated $203K sold.

Caprock Group first reported a position in HZNP in Q4 2018 and held it in 14 quarters. The position peaked at $404K in Q4 2019. 553 funds tracked by Wall St. Rank hold HZNP as of Q1 2023.

  • Caprock Group reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2023 after selling out during the quarter.
  • Caprock Group sold 1,784 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2023, an estimated $203K.
  • Caprock Group first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2018 and held it in 14 quarters.
  • Caprock Group's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $404K in Q4 2019.
  • 553 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2023.

Based on Caprock Group's 13F filing for Q1 2023, filed 26 Apr 2023.